The neurobiology of the substantia nigra pars compacta: From motor to sleep regulation

Journal of Neural Transmission, Supplementa

Volumn , Issue 73, 2009, Pages 135-145

  Lima, Marcelo M S ^b   Reksidler, Angela B B ^a   Vital, Maria A B F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b NONE

Author keywords

6 OHDA; Motor; MPTP; Sleep; Substantia nigra pars compacta

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENYLATE CYCLASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BENSERAZIDE; CARBIDOPA; CYCLOOXYGENASE 2; DOPA; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; GAMMA INTERFERON; HALOPERIDOL; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEVODOPA; LIPOPOLYSACCHARIDE; NEUROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; OXIDOPAMINE; PROTEIN P53; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE;

APOPTOSIS; BASAL GANGLION; CELL INCLUSION; CLINICAL FEATURE; DISEASE MODEL; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; HUMAN; LOCOMOTION; MICROGLIA; MOTOR PERFORMANCE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROBIOLOGY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SINGLE DRUG DOSE; SLEEP; SLEEP REGULATION; SLEEP WAKING CYCLE; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA; ZONA COMPACTA; ANIMAL; BIOLOGICAL MODEL; METHODOLOGY; MOTOR ACTIVITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MODELS, BIOLOGICAL; MOTOR ACTIVITY; NEUROBIOLOGY; PARKINSON DISEASE; SLEEP; SUBSTANTIA NIGRA;

EID: 77952317195     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-211-92660-4_11     Document Type: Review

References (104)

1. Andrade LA, Lima JG, Tufik S, Bertolucci PH, Carlini EA (1987) Rem sleep deprivation in an experimental model of Parkinson's disease. Arq Neuropsiquiatr 45(3):217-223
2. Arnulf I (2006) Sleep and wakefulness disturbances in Parkinson's disease. J Neural Transm Suppl 70:357-360
3. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, Lacomblez L, Golmard JL, Derenne JP, Agid Y (2002) Parkinson's disease and sleepiness: an integral part of PD. Neurology 58(7):1019-1024
4. Asanuma M, Miyazaki I (2006) Nonsteroidal anti-inflammatory drugs in Parkinson's disease: possible involvement of quinone formation. Expert Rev Neurother 6(9):1313-1325
5. Barbeau A et al. (1961) Les catecholamines dans la maladie de Parkinson. In Georg (ed) CMonoamines et Syste'me Nerveux Central. Geneva, pp. 247-262
6. Barnham JK, Masters AB, Bush A (2004) Neurodegenerative disease and oxidative stress. Nat Rev Drug Discov 3:205-214
7. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem 73(3):1127-1137
8. Birkmayer W, Hornykiewicz O (1961) der L-3, 4-dioxyphenylalanin (L-DOPA)-effect bei der Parkinson-akinese. Klin Wschr 73:787-788
9. Bové J, Prou D, Perier C, Przedborski S (2005) Toxin-induced models of Parkinsońs disease. The Journal of the American Society for Experimental NeuroTherapeutics 2:484-494
10. Braga R, Kouzmine I, Canteras NS, Da Cunha C (2005) Lesion of the substantia nigra, pars compacta impairs delayed alternation in a Y-maze in rats. Exp Neurol 192(1):134-141
11. Carlini EA (1983) REM sleep deprivation and dopamine in the CNS. Rev Pure Appl Pharmacol Sci 4(1):1-25
12. Carlini EA, Lindsey CJ, Tufik S (1977) Cannabis, catecholamines, rapid eye movement sleep and aggressive behaviour. Br J Pharmacol 61(3):371-379
13. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A (2003) Nonsteroidal antiinflammatory drugs and the risk of Parkinson disease. Arch Neurol 60(8):1059-1064
14. Chiba K, Trevor A, CJ N (1984) Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 120:574-578
15. Cotzias GC (1968) L-DOPA for Parkinsonism. N Engl J Med 278:630
16. Cui K, Luo X, Xu K, Vem Murthy MR (2004) Role of oxidative stress in neurodegeneration: recent developments in assay methods for oxidative stress and nutraceutical antioxidants. Prog Neuropsychopharmacol Biol Psychiatry 28:771-799
17. Da Cunha C, Gevaerd MS, Vital MA, Miyoshi E, Andreatini R, Silveira R, Takahashi RN, Canteras NS (2001) Memory disruption in rats with nigral lesions induced by MPTP: a model for early Parkinson's disease amnesia. Behav Brain Res 124(1):9-18
18. Dahan L, Astier B, Vautrelle N, Urbain N, Kocsis B, Chouvet G (2007) Prominent Burst Firing of Dopaminergic Neurons in the Ventral Tegmental Area during Paradoxical Sleep. Neuropsychopharmacology 32(6):1232-1241
19. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909
20. De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, Roze E, Willer JC, Derenne JP, Agid Y, Arnulf I (2007) Restoration of normal motor control in Parkinson's disease during REM sleep. Brain 130 (Pt 2):450-456
21. Deumens R, Blokland A, Prickaerts J (2002) Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol 175:303-307
22. Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E (2006) Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res 1095(1):167-177
23. Dzirasa K, Ribeiro S, Costa R, Santos LM, Lin SC, Grosmark A, Sotnikova TD, Gainetdinov RR, Caron MG, Nicolelis MA (2006) Dopaminergic control of sleep-wake states. J Neurosci 26(41):10577-10589
24. Ehringer H, Hornykiewicz O (1960) Verteilung von noradrenalin und dopamine (3-hydroxtyramin) im gehirn des menschen und ihr verhalten bei erkankungen des extrapyamidalen systems. Klin Wschr 38:1236-1239
25. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G (2007) Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 205(2):295-312
26. Faull RL, Laverty R (1969) Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol 23:332-340
27. Ferger B, Teismann P, Earl CD, Kuschinsky K, Oertel WH (1999) Salicylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice. Naunyn Schmiedebergs Arch Pharmacol 360(3):256-261
28. Ferro MM, Bellissimo MI, Anselmo-Franci JA, Angellucci ME, Canteras NS, Da Cunha C (2005) Comparison of bilaterally 6-OHDA-and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J Neurosci Methods 148(1):78-87
29. Franco J, Prediger RD, Pandolfo P, Takahashi RN, Farina M, Dafre AL (2007) Antioxidant responses and lipid peroxidation following intranasal 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) administration in rats: increased susceptibility of olfactory bulb. Life Sci 80(20):1906-1914
30. Gainetdinov RR, Fumagalli F, Jones SR, Caron MG (1997) Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325
31. Gevaerd MS, Miyoshi E, Silveira R, Canteras NS, Takahashi RN, Da Cunha C (2001) L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats. Int J Neuropsychopharmacol 4(4):361-370
32. Hastings TG (1995) Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 64(2):919-924
33. Heikkila RE, Hess A, Duvoisin RC (1984) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in mice. Science 224:1451-1453
34. Hogl B, Rothdach A, Wetter TC, Trenkwalder C (2003) The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 28(10):1866-1870
35. Iversen SD, Iversen LL (2007) Dopamine: 50 years in perspective. Trends Neurosci 30(5):188-193
36. Jones BE (2003) Arousal systems. Front Biosci 8: s438-s451
37. Kebabian JW, Calne BD (1979) Multiple receptors for dopamine. Nature 277:93-96
38. Kebabian JW, Petzold GL, Greengard P (1972) Dopamine-sensitive anenylate cyclase in caudate nucleus of rat brain and its similarity to the dopamine receptor. Proc Natl Acad Sci USA 69:2145-2149
39. Laloux C, Derambure P, Kreisler A, Houdayer E, Bruezière S, Bordet R, Destée A, Monaca C (2008) MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp Brain Res 186:635-642
40. Lane E, Dunnett S (2007) Animal models of Parkinsońs disease and L-dopa induced dyskinesia: How close are we to the clinic? Psychopharmacology (Berl) 199:303-312
41. Lang AE, Lozano AM (1998) Parkinsońs disease. First of two parts. N Engl J Med 339:1044-1053
42. Langston JW, Ballard PA Jr (1983) Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med 309(5):310
43. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979-980
44. Larsen JP, Tandberg E (2001) Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 15(4):267-275
45. Lee CS, Sauer H, Bjorklund A (1996) Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72:641-653
46. Lelkes Z, Stenberg D, Porkka-Heiskanen T (1991) Effect of MPTP on sleep in rats. Sleep Res 20 A: 154
47. Liang LP, Patel M (2004) Iron-sulfur enzyme mediated mitochondrial superoxide toxicity in experimental Parkinson's disease. J Neurochem 90(5):1076-1084
48. Lima MMS, Braga Reksidler A, Marques Zanata S, Bueno Machado H, Tufik S, Vital MA (2006) Different parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 1101(1):117-125
49. Lima MMS, Andersen ML, Reksidler AB, Vital MABF, Tufik S (2007) The role of the substantia nigra pars compacta in regulating sleep patterns in rats. PLoS ONE 2: e513
50. Lima MM, Andersen ML, Reksidler AB, Silva A, Zager A, Zanata SM, Vital MA, Tufik S (2008a) Blockage of dopaminergic D (2) receptors produces decrease of REM but not of slow wave sleep in rats after REM sleep deprivation. Behav Brain Res 188(2):406-411
51. Lima MMS, Reksidler AB, Vital MABF (2008b) The dopaminergic dilema: Sleep or wake? implications in Parkinsońs disease. Biosci Hypothesis 1:9-13
52. Lu J, Jhou TC, Saper CB (2006) Identification of wake-active dopaminergic neurons in the ventral periaqueductal gray matter. J Neurosci 26(1):193-202
53. Marsden CA (2006) Dopamine: the rewarding years. Br J Pharmacol 147 (Suppl 1): S136-S144
54. McCarley RW (2007) Neurobiology of REM and NREM sleep. Sleep Med 8(4):302-330
55. Mena-Segovia J, Bolam JP, Magill PJ (2003) Pedunculopontine nucleus and basal ganglia: distant relatives or part of the same family? Trends Neurosci 27:585-588
56. Meredith GE, Totterdell S, Potashkin JA, Surmeier J (2008) Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14: S112-S115
57. Miyawaki E, Lyons K, Pahwa R, Troster AI, Hubble J, Smith D, Busenbark K, McGuire D, Michalek D, Koller WC (1997) Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 20(6):523-530
58. Miyoshi E, Wietzikoski S, Camplessei M, Silveira R, Takahashi RN, Da Cunha C (2002) Impaired learning in a spatial working memory version and in a cued version of the water maze in rats with MPTP-induced mesencephalic dopaminergic lesions. Brain Res Bull 58(1):41-47
59. Monti JM (1982) Catecholamines and the sleep-wake cycle. I. EEG and behavioral arousal. Life Sci 30(14):1145-1157
60. Monti JM, Monti D (2007) The involvement of dopamine in the modulation of sleep and waking. Sleep Med Rev 11(2):113-133
61. Nunes GP, Tufik S, Nobrega JN (1994) Autoradiographic analysis of D1 and D2 dopaminergic receptors in rat brain after paradoxical sleep deprivation. Brain Res Bull 34(5):453-456
62. Pace-Schott EF, Hobson JA (2002) The neurobiology of sleep: genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 3(8):591-605
63. Perry JC, Da Cunha C, Anselmo-Franci J, Andreatini R, Miyoshi E, Tufik S, Vital MA (2004) Behavioural and neurochemical effects of phosphatidylserine in MPTP lesion of the substantia nigra of rats. Eur J Pharmacol 484 (2-3): 225-233
64. Porkka-Heiskanen T, Tuomisto L, Ylinen M, Stenberg D (1994) The effect of REM sleep deprivation on histamine concentrations in different brain areas. Life Sci 54(22):1719-1726
65. Portas CM, Bjorvatn B, Ursin R (2000) Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies. Prog Neurobiol 60(1):13-35
66. Porter CC, Totaro JA, Stone CA (1963) Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 140:308-316
67. Prediger RD, Batista LC, Medeiros R, Pandolfo P, Florio JC, Takahashi RN (2006) The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease. Exp Neurol 202(2):391-403
68. Przedborski S (2005) Pathogenesis of nigral cell death in Parkinson's disease. Parkinsonism Relat Disord 11 (Suppl 1): S3-S7
69. Przedborski S, Tieu K, Perier C, Vila M (2004) MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36(4):375-379
70. Pulst S-M (2003) Genetics of Movement disorders. Academic Press San Diego, California USA
71. Pungor K, Papp M, Kekesi K, Juhasz G (1990) A novel effect of MPTP: the selective suppression of paradoxical sleep in cats. Brain Res 525(2):310-314
72. Reavill C, Jenner P, Marsden CD (1980) Metabolite involvement in bromocriptine-induced circling behaviour in rodents. J Pharm Pharmacol 32(4):278-284
73. Reksidler AB, Lima MMS, Zanata SM, Machado HB, da Cunha C, Andreatini R, Tufik S, Vital MABF (2007) The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats. Eur J Pharmacol 560 (2-2): 163-175
74. Reksidler AB, Lima MMS, Dombrowski P, Andersen ML, Zanata SM, Andreatini R, Tufik S, Vital MABF (2008) Repeated intranigral MPTP administration: A new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 167(2):268-277
75. Reksidler AB, Lima MMS, Dombrowski P, Barnabé GF, Andersen ML, Tufik S, Vital MABF (2009) Distinct effects of intranigral L-DOPA infusion in the MPTP rat model of Parkinson's disease. In: G. Di Giovanni, V. Di Matteo, E. Esposito (ed) Birth, life and death of dopaminergic neurons in the Substantia Nigra. Journal of Neural Transmission, Vol 73, Springer Heidelberg
76. Rollema H, Kuhr WG, Kranenborg G, De Vries J, Van den Berg C (1988) MPP+-induced efflux of dopamine and lactate from rat striatum have similar time courses as shown by in vivo brain dialysis. J Pharmacol Exp Ther 245(3):858-866
77. Sairam K, Saravanan KS, Banerjee R, Mohanakumar KP (2003) Nonsteroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res 966(2):245-252
78. Schapira AHV, Bezard E, Brotchie J (2006) Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov 5:845-854
79. Sedelis M, Schwarting RKW, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 125:109-125
80. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptics/dopamine receptors. Nature 261:717-719
81. Serra PA, Sciola L, Delogu MR, Spano A, Monaco G, Miele E (2002) The neurotoxin MPTP induces apoptosis in mouse nigro-striatal glia Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277:34451-34461
82. Siegel JM (2004) Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 55:125-148
83. Simola N, Morelli M, Carta AR (2007) The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res 11 (3-4): 151-167
84. Sonsalla PK, Heikkila RE (1986) The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur Eur. J. Pharmacol 129:339-345
85. Speciale SG (2002) Insights into parkinsonian neurodegeneration. Neurotoxicol Teratol 24:607-620
86. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC (1998) The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84(4):1177-1185
87. Steininger TL, Alam MN, Gong H, Szymusiak R, McGinty D (1999) Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat. Brain Res 840 (1-2): 138-147
88. Steriade M, Amzica F, Nunez A (1993) Cholinergic and noradrenergic modulation of the slow (approximately 0.3 Hz) oscillation in neocortical cells. J Neurophysiol 70(4):1385-1400
89. Sundström E, Strömberg I, Tsutsumi T, Olson I, Josson G (1987) Studies on the effect of 1-methy-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res 405:26-38
90. Tandberg E, Larsen JP, Karlsen K (1998) A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 13(6):895-899
91. Tatton NA, Kish SJ (1997) In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine- treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77:1037-1048
92. Teismann P, Ferger B (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39(2):167-174
93. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003a) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100(9):5473-5478
94. Teismann P, Vila M, Choi DK, Tieu K, Wu DC, Jackson-Lewis V, Przedborski S (2003b) COX-2 and neurodegeneration in Parkinson's disease. Ann NY Acad Sci 991:272-277
95. Thobois S, Delamarre-Damier F, Derkinderen P (2005) Treatment of motor dysfunction in Parkinson's disease: an overview. Clin Neurol Neurosurg 107(4):269-281
96. Thomson F et al (2001) Parkinson's disease: treatment. Pharm J 267:600-613
97. Truong DD, Bhidayasiri R, Wolters E (2008) Management of nonmotor symptoms in advanced Parkinson disease. J Neurol Sci 266 (1-2): 216-228
98. Tufik S (1981a) Changes of response to dopaminergic drugs in rats submitted to REM-sleep deprivation. Psychopharmacology (Berl) 72(3):257-260
99. Tufik S (1981b) Increased responsiveness to apomorphine after REM sleep deprivation: supersensitivity of dopamine receptors or increase in dopamine turnover? J Pharm Pharmacol 33(11):732-738
100. Tufik S, Lindsey CJ, Carlini EA (1978) Does REM sleep deprivation induce a supersensitivity of dopaminergic receptors in the rat brain? Pharmacology 16(2):98-105
101. Ungerstedt U (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 5:107-110
102. Ungerstedt U (1971a) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:95-122
103. Ungerstedt U (1971b) Postsynaptic supersensitivity after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 367:69-93
104. Whitton PS (2007) Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150(8):963-976